Pertuzumab combined with trastuzumab plus chemotherapy adds approximately 16 months to median overall survival times for patients with HER2-positive metastatic breast cancer
At ESMO 2014, Prof Sandra Swain presents the results of a phase III trial (CLEOPATRA). The results show that patients with HER2-positive metastatic breast cancer treated with pertuzumab combined with ...
Author: EMJ
Added: 10/03/2014
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts